US · WGS
GeneDx Holdings Corp.
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- Stamford, CT 06902
- Website
- genedx.com
Price · as of 2025-12-31
$65.38
Market cap 2.3B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $161.40 | +146.86% |
| Intrinsic Value(DCF) | $30.77 | -52.94% |
| Graham-Dodd Method(GD) | $7.05 | -89.22% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $569.91 | ||||
| 2021 | $93.72 | $42.95 | $0.00 | $0.00 | $0.00 |
| 2022 | $11.32 | $4.53 | $0.00 | $0.00 | $0.00 |
| 2023 | $8.39 | $18.96 | $0.00 | $0.00 | $35.27 |
| 2024 | $98.01 | $84.08 | $0.00 | $0.00 | $0.00 |
| 2025 | $74.20 | $161.40 | $1.34 | $7.05 | $0.00 |
AI valuation
Our deep-learning model estimates GeneDx Holdings Corp.'s (WGS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $161.40
- Current price
- $65.38
- AI upside
- +146.86%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$30.77
-52.94% upside
Graham-Dodd
$7.05
-89.22% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| WGS | GeneDx Holdings Corp. | $65.38 | 2.3B | +147% | -53% | -89% | — | -94.92 | 6.47 | 4.67 | 298.22 | — | 15.81 | 69.74% | -2.76% | -4.92% | -7.60% | -4.61% | -4.25% | 0.49 | -4.65 | 2.46 | 2.26 | 7.09 | -6237.00% | 3997.00% | -14196.00% | 0.71% | 0.31 | 5.60% | 0.00% | 0.00% | 0.00% | -167.43 | 138.55 | 4.62 | 2.21 |
| CRNX | Crinetics Pharmaceuticals… | $41.10 | 4.21B | +36% | -54% | — | — | -8.22 | 3.86 | 705.95 | -6.17 | -24.08 | 3.86 | 80.15% | -9534.48% | -8585.18% | -40.17% | -2936.77% | -36.34% | 0.05 | — | 12.32 | 12.09 | 0.11 | 3415.00% | 42166.00% | 6695.00% | -10.03% | -4.44 | -2180.46% | 0.00% | 0.00% | 0.00% | -5.51 | -7.42 | 525.26 | 14.87 |
| HNGE | Hinge Health, Inc. | $42.76 | 3.37B | +11% | +616% | — | — | -6.72 | 9.38 | 6.04 | -5.91 | -0.20 | 11.39 | 79.65% | -92.94% | -89.86% | -132.86% | 6793.55% | -74.51% | 0.02 | — | 1.47 | 1.19 | 0.37 | 336000.00% | 5058.00% | 27749.00% | 4.81% | 0.47 | -2122.88% | 0.00% | 0.00% | 1.83% | -5.85 | 18.72 | 5.44 | 2.49 |
| IMVT | Immunovant, Inc. | $27.73 | 5.64B | — | — | — | — | -6.14 | 3.59 | — | -4.18 | -13.59 | 3.59 | 0.00% | — | — | -62.46% | 3667.16% | -57.36% | 0.00 | — | 11.16 | 10.42 | 1.63 | 4521.00% | — | 7552.00% | -14.82% | -5.47 | 3152.27% | 0.00% | 0.00% | 3.09% | -4.17 | -4.85 | — | 19.16 |
| KYMR | Kymera Therapeutics, Inc. | $91.35 | 7.31B | -43% | -53% | -100% | -68% | -24.42 | 4.81 | 193.97 | -22.56 | -102.50 | 4.81 | 100.00% | -891.33% | -794.39% | -25.78% | -55.98% | -22.89% | 0.05 | -1403.21 | 10.47 | 10.19 | 0.91 | 2383.00% | -1672.00% | 1302.00% | -3.08% | -2.80 | -37.55% | 0.00% | 0.00% | 3.19% | -19.57 | -29.18 | 174.43 | 27.01 |
| NAMS | NewAmsterdam Pharma Compa… | $35.46 | 4.08B | +16% | -57% | — | +102% | — | 5.50 | 166.90 | -12.87 | — | 5.50 | 99.74% | -1002.90% | -905.74% | 0.00% | 1564.53% | 0.00% | 0.00 | — | 7.88 | 7.69 | 2.02 | -3164.00% | -5061.00% | -704.00% | -3.94% | -1.72 | 1026.20% | 0.00% | — | 0.00% | -13.82 | -21.07 | 138.63 | 24.84 |
| OPCH | Option Care Health, Inc. | $32.46 | 5.27B | +26% | -61% | -85% | -17% | 24.09 | 3.77 | 0.89 | 10.05 | 592.65 | -16.55 | 19.26% | 5.98% | 3.67% | 15.20% | 15.01% | 6.04% | 0.00 | 2.70 | 1.53 | 0.85 | -0.49 | 407.00% | 1303.00% | -1019.00% | 5.17% | 0.31 | 15.65% | 0.00% | 0.00% | 26.95% | 14.11 | 18.45 | 0.84 | 3.52 |
| OSCR | Oscar Health, Inc. | $13.64 | 3.54B | +238% | +3,520% | — | — | -8.28 | 3.75 | 0.31 | -0.28 | — | 3.75 | 14.38% | -3.39% | -3.79% | -44.49% | 23.17% | -7.93% | 0.44 | -22.52 | 0.95 | 0.91 | 5.99 | -186594.00% | 2750.00% | 1138.00% | 28.86% | 0.23 | -61.87% | 0.00% | 0.00% | 30.44% | -0.27 | 0.10 | 0.01 | 1.28 |
| PRVA | Privia Health Group, Inc. | $23.75 | 2.92B | +1,602% | +12,603% | +22,024% | +23,094% | 0.10 | 0.00 | 1.38 | -8677.07 | 0.16 | 0.01 | 9.40% | 1.61% | 1079.64% | 8.06% | 0.02% | 4.34% | 0.01 | — | 1.60 | 1.55 | -8731.62 | 6364.00% | 2226.00% | 15646682.00% | 5557.73% | 0.29 | 122.18% | 0.00% | 0.00% | 15990.70% | -13647.35 | -2.86 | -220.09 | 0.14 |
| TMDX | TransMedics Group, Inc. | $145.26 | 4.96B | -12% | +2,727% | -71% | +68% | 26.26 | 10.56 | 8.25 | 33.53 | 6.87 | 10.87 | 59.92% | 17.93% | 31.43% | 54.24% | 25.12% | 20.33% | 0.99 | 7.88 | 7.14 | 6.41 | -0.13 | 38218.00% | 3713.00% | -26504.00% | 2.67% | 2.16 | 30.90% | 0.00% | 0.00% | 4.01% | 45.85 | 37.27 | 8.22 | 6.19 |
| VKTX | Viking Therapeutics, Inc. | $33.84 | 3.91B | — | — | — | — | -10.44 | 5.88 | — | -7.76 | -4.84 | 5.88 | 0.00% | — | — | -47.34% | 896.45% | -44.29% | 0.00 | -7023.96 | 9.33 | 9.21 | 0.42 | 21584.00% | — | 21745.00% | -7.42% | -3.64 | 635.14% | 0.00% | 0.00% | 3.73% | -7.76 | -10.95 | — | 27.00 |
About GeneDx Holdings Corp.
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
- CEO
- Katherine A. Stueland
- Employees
- 1K
- Beta
- 2.02
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($30.77 ÷ $65.38) − 1 = -52.94% (DCF, example).